Company intelligence / Profile preview
Vitalex Biosciences
Irvine, California, United Statesvitalexbiosciences.com ↗
- Ownership
- Private
- Employees
- ~1
- Development stage
- Other
01
Overview
Vitalex is advancing a monoclonal antibody (VX-01) for mucormycosis and a dual-antigen vaccine (VXV-01) targeting invasive fungal infections and Gram-negative bacteria, both supported by significant NIH/NIAID funding. Main candidates have demonstrated efficacy in animal models; clinical trials have not yet started[5][1][2][6].
- Therapeutic areas
- Infectious Diseases
- Modalities
- Monoclonal antibodyVaccineDiagnostic
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Appili Therapeutics (co-development of VXV-01)[2]The Lundquist Institute (incubator/academic collaboration)[5]JOINN Biologics (manufacturing/CDMO partner for VX-01)[5]BrevisRefero Corporation (CMC services for VX-01)[5]
Beyond the preview
Go deeper on Vitalex Biosciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Vitalex Biosciences.